Pulse Biosciences Inc (NASDAQ:PLSE) Director Maky Zanganeh purchased 18,240 shares of Pulse Biosciences stock in a transaction dated Monday, March 20th. The stock was bought at an average cost of $23.34 per share, with a total value of $425,721.60. Following the completion of the purchase, the director now owns 263,935 shares in the company, valued at approximately $6,160,242.90. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link.

Shares of Pulse Biosciences Inc (NASDAQ:PLSE) traded down 5.96% during mid-day trading on Monday, hitting $23.03. 426,087 shares of the stock were exchanged. The firm’s market cap is $306.62 million. Pulse Biosciences Inc has a 1-year low of $4.03 and a 1-year high of $25.15. The company’s 50-day moving average is $13.18 and its 200-day moving average is $7.81.

Your IP Address:

About Pulse Biosciences

Pulse Biosciences, Inc, formerly Electroblate, Inc, is a development-stage medical device company using a platform technology called Nano-Pulse Electro-Signaling (NPES). NPES is a local and drug-free technology that utilizes nanosecond pulsed electric fields to induce cell signaling and the activation of cellular pathways in tissue.

5 Day Chart for NASDAQ:PLSE

Receive News & Stock Ratings for Pulse Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulse Biosciences Inc and related stocks with our FREE daily email newsletter.